CY1106359T1 - Νεες μεθοδοι και συνθεσεις πepιεχουσες οπιοειδη και ανταγωνιστες αυτων - Google Patents

Νεες μεθοδοι και συνθεσεις πepιεχουσες οπιοειδη και ανταγωνιστες αυτων

Info

Publication number
CY1106359T1
CY1106359T1 CY20071100318T CY071100318T CY1106359T1 CY 1106359 T1 CY1106359 T1 CY 1106359T1 CY 20071100318 T CY20071100318 T CY 20071100318T CY 071100318 T CY071100318 T CY 071100318T CY 1106359 T1 CY1106359 T1 CY 1106359T1
Authority
CY
Cyprus
Prior art keywords
compositions
opioids
methods
antagonists
preparing
Prior art date
Application number
CY20071100318T
Other languages
English (en)
Inventor
John J. Farrar
Original Assignee
Adolor Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adolor Corporation filed Critical Adolor Corporation
Publication of CY1106359T1 publication Critical patent/CY1106359T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Νέες μέθοδοι και συνθέσεις που περιέχουν οπιοειδή και ανταγωνιστές οπιοειδών. Σε προτιμώμενες ενσωματώσεις, οι μέθοδοι και οι συνθέσεις περιέχουν οπιοειδή και ενώσεις ανταγωνιστών οπιοειδών περιφερειακών mu. Οι μέθοδοι και οι συνθέσεις είναι ιδιαιτέρως κατάλληλες για την θεραπευτική και/ή την προληπτική αγωγή παράπλευρων δράσεων συνδεομένων με οπιοειδή στις οποίες περιλαμβάνονται, παραδείγματος χάρη, δυσκοιλιότητα, έμετος και/ή ναυτία. Τα Σχήματα 2Α και 2Β είναι γραφικές παραστάσεις μελετών επί της αναστολής της ναυτίας και του εμέτου με χρήση μεθόδων συμφώνων προς μια ενσωμάτωση της παρούσας εφεύρεσης.
CY20071100318T 1999-11-29 2007-03-07 Νεες μεθοδοι και συνθεσεις πepιεχουσες οπιοειδη και ανταγωνιστες αυτων CY1106359T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45080699A 1999-11-29 1999-11-29
PCT/US2000/042315 WO2001037785A2 (en) 1999-11-29 2000-11-29 Novel methods and compositions involving opioids and antagonists thereof

Publications (1)

Publication Number Publication Date
CY1106359T1 true CY1106359T1 (el) 2011-10-12

Family

ID=23789563

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100318T CY1106359T1 (el) 1999-11-29 2007-03-07 Νεες μεθοδοι και συνθεσεις πepιεχουσες οπιοειδη και ανταγωνιστες αυτων

Country Status (13)

Country Link
EP (1) EP1244447B1 (el)
JP (1) JP2003528819A (el)
AU (1) AU784541B2 (el)
CA (1) CA2392362A1 (el)
CY (1) CY1106359T1 (el)
DE (1) DE60032940T2 (el)
DK (1) DK1244447T3 (el)
ES (1) ES2278647T3 (el)
IL (2) IL149600A0 (el)
MX (1) MXPA02005335A (el)
NZ (1) NZ518562A (el)
PT (1) PT1244447E (el)
WO (1) WO2001037785A2 (el)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
NZ505193A (en) 1997-12-22 2003-03-28 Euro Celtique S Opioid agonist/antagonist combinations
ATE431145T1 (de) 2000-02-08 2009-05-15 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
CA2446550C (en) 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
DE60234183D1 (de) * 2001-06-05 2009-12-10 Univ Chicago Verwendung von methylnaltrexon zur behandlung von immunsuppression
JP4256259B2 (ja) 2001-07-18 2009-04-22 ユーロ−セルティーク エス．エイ． オキシコドン及びナロキソンの医薬配合物
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US7914818B2 (en) 2001-08-06 2011-03-29 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
ES2733051T1 (es) 2002-04-05 2019-11-27 Euro Celtique Sa Matriz para liberación sostenida, invariable e independiente de compuestos activos
PT1551372T (pt) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
DK2368554T3 (en) 2003-04-08 2015-01-26 Progenics Pharm Inc A pharmaceutical composition comprising methylnaltrexone
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US7700626B2 (en) 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
WO2006064780A1 (ja) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. 便秘治療剤
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20060211733A1 (en) * 2005-03-04 2006-09-21 Adolor Corporation Methods of preventing and treating opioid bowel dysfunction
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662390B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
WO2006126529A1 (ja) * 2005-05-25 2006-11-30 Shionogi & Co., Ltd. ６，７－不飽和－７－カルバモイル置換モルヒナン誘導体
EP1762569A1 (en) * 2005-09-12 2007-03-14 Alcasynn Pharmaceuticals Gmbh Novel 6-amino-morphinan derivatives, method of manufacturing them and their application as analgesics
EP2034977B1 (en) 2006-04-21 2011-07-13 DSM IP Assets B.V. Use of opioid receptor antagonists
KR101486228B1 (ko) 2006-06-19 2015-01-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
WO2008121352A2 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof
EP2139890B1 (en) 2007-03-29 2014-06-25 Wyeth LLC Peripheral opioid receptor antagonists and uses thereof
CA2682125C (en) 2007-03-29 2015-06-16 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
KR101519682B1 (ko) 2007-08-09 2015-05-19 렌슬러 폴리테크닉 인스티튜트 4급 오피오이드 카르복스아미드
JP5905198B2 (ja) * 2007-10-01 2016-04-20 ザ ユニヴァーシティー オヴ シカゴ 薬剤誘発性吐き気のオピオイド拮抗薬による治療
CN103275004A (zh) * 2007-11-30 2013-09-04 普渡制药公司 苯并吗啡烷化合物
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2730578A1 (en) 2008-02-06 2014-05-14 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnal trexone
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
EP2405915B1 (en) 2009-03-10 2018-10-24 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
ES2729679T3 (es) 2009-12-04 2019-11-05 Alkermes Pharma Ireland Ltd Derivados de morfinano para el tratamiento de la sobredosis de fármacos
US8436175B2 (en) 2010-03-22 2013-05-07 Rensselaer Polytechnic Institute Carboxamide bioisosteres of opiates
SI2608670T1 (sl) 2010-08-23 2019-04-30 Alkermes Pharma Ireland Limited Postopki za zdravljenje pridobivanja teže, ki je posledica uporabe antipsihotičnih zdravil
SI2725908T1 (sl) 2011-06-29 2017-10-30 Alkermes, Inc. Periferno delujoče opioidne spojine
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US9487531B2 (en) * 2013-04-17 2016-11-08 BioPharma Works LLC Compounds for treatment of pain
WO2014172478A1 (en) 2013-04-17 2014-10-23 VOLKMANN Robert Compounds for treatment of pain
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
KR102201609B1 (ko) * 2019-04-19 2021-01-12 연성정밀화학(주) 날데메딘의 제조방법
WO2022101444A1 (en) 2020-11-12 2022-05-19 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4769372A (en) * 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
IL86061A (en) * 1987-04-16 1992-07-15 Lilly Co Eli Derivatives of trans-3,4-isomer of 4-methyl-4-phenyl-piperidines,process for their preparation and pharmaceutical compositions containing them
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists

Also Published As

Publication number Publication date
NZ518562A (en) 2005-04-29
JP2003528819A (ja) 2003-09-30
WO2001037785A3 (en) 2002-01-10
ES2278647T3 (es) 2007-08-16
EP1244447A2 (en) 2002-10-02
WO2001037785A2 (en) 2001-05-31
AU3970601A (en) 2001-06-04
CA2392362A1 (en) 2001-05-31
IL149600A0 (en) 2002-11-10
WO2001037785A9 (en) 2002-08-29
AU784541B2 (en) 2006-04-27
PT1244447E (pt) 2007-02-28
IL149600A (en) 2010-06-16
DE60032940T2 (de) 2007-11-08
EP1244447B1 (en) 2007-01-10
DK1244447T3 (da) 2007-04-23
EP1244447A4 (en) 2003-06-04
DE60032940D1 (de) 2007-02-22
MXPA02005335A (es) 2003-01-28

Similar Documents

Publication Publication Date Title
CY1106359T1 (el) Νεες μεθοδοι και συνθεσεις πepιεχουσες οπιοειδη και ανταγωνιστες αυτων
CY1106600T1 (el) Ανθεκτικη, στη φθορα συνεξωθημενη μορφη δοσολογιας που περιεχει εναν ενεργο παραγοντα και εναν ανταγωνιστικο παραγοντα και διαδικασια παρασκευης αυτης
TR199801594A2 (xx) CCR-3 resept�r antagonistleri.
EA200101177A1 (ru) Производные индола в качестве антагонистов прогестерона
TR200200795T2 (tr) 5-HT1B antagonistleri olarak piperazin türevleri
ATE349440T1 (de) Als antikrebsmittel verwendbare heterocyklische derivate
CY1106257T1 (el) ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΙΔΑΖΙΝΟ [4,5-(b)]-ΙΝΔΟΛΗ -1-ΑΚΕΤΑΜΙΔΗ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΣΚΕΥΑΣΜΑΤΩΝ ΠΟΥ ΠΡΟΟΡΙΖΟΝΤΑΙ ΓΙΑ ΝΟΣΟΥΣ ΠΟΥ ΣΥΝΔΕΟΝΤΑΙ ΜΕ ΤΗ ΔΥΣΛΕΙΤΟΥΡΓΙΑ ΤΩΝ ΥΠΟΔΟΧΕΩΝ ΠEPΙΦEPΙΚΟΥ ΤΥΠΟΥ ΣΤΙΣ ΒΕΝΖΟΔΙΑΖΕΠΙΝΕΣ
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
CH1175401H9 (de) Piperazin Derivate verwendbar als CCR5 Antagonist en
TR199801555T2 (xx) Topoizomeraz inhibit�rleri olarak koralin analoglar�.
CY1108339T1 (el) Παραγωγα spiro(2h-1-benzopyran-2,4´-piperidine) ως αναστολεις της μεταφορας γλυκινης
DE60021282D1 (de) Carbamat-derivate als muscarin-rezeptor antonisten
HUT74992A (en) Use of serotonin antagonist indol derivatives for producing pharmaceutical compositions using for treating fibromyalgia
DE60135485D1 (de) Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa
ES2072096T3 (es) 4-fenilpiperidinas n-sustituidas antagonistas de opioides.
HUP0301573A2 (hu) Szubsztituált arilpirazinok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
BR9206237A (pt) Uso de derivados de tetrahidrocarbazole como receptores agonistas 5-HT1.
SE9702773D0 (sv) Novel compounds
EA200300593A1 (ru) Соединения пиперазинилпиразинов в качестве агонистов или антагонистов серотонин 5-ht2 рецептора
CY1111698T1 (el) Συνδυασμος που περιλαμβανει εναν ανταγωνιστη υποδοχεα ατ1 και εναν ενισχυτη εκκρισης ινσουλινης ή εναν ευαισθητοποιητη ινσουλινης
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
ME00056B (me) Kombinacija kombrestatina i anti-kancer agensa
TR200200359T2 (tr) Cgrp Antagonist'lerinin ve cgrp-release (Gevşeme)-Engelleyici Menopoza Bağlı Deri Kızarıklıklarında Kullanılması
TR199900732T2 (xx) PDE IV inhibe eden 2-siyanoiminoimidazol t�revleri.
TR199902848T2 (xx) Ergolin t�revleri ve bunlar�n somatostatin resept�r antagonist olarak kullan�mlar�